Stockreport
Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
The company's shares have more than doubled over the trailing 12-month period. However, as is almost always the case with smaller drugmakers, Mirum Pharmaceuticals isn't consistently profitable. If it can make solid progress toward that goal (and elsewhere), the stock might be worth investing in today. Is Mirum close to posting consistent green on the bottom line? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Mirum Pharmaceuticals is a biotech that markets therapies for underserved diseases. The company developed Livmarli, a treatment for severe itching in patients with Alagille syndrome, a rare condition that can lead to liver damage. Mirum's lineup also included Cholbam, a medication indicated for the treatment of bile acid disorders, and Chenodal, which helps treat gallstones in patients undergoing gallbladder surgery. Mirum Pharmaceuticals acquired Chol
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MIRM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MIRM alerts
MIRM alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
NEWS
NEWS
- Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.[MarketBeat]
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 [Yahoo! Finance][Yahoo! Finance]
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026[Business Wire]
- Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $130.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.[MarketBeat]
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)[Business Wire]
- More
MIRM
SEC Filings
SEC Filings
- 2/17/26 - Form 4
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 144
- MIRM's page on the SEC website
- More